Diagnosis of MGRS in Patients With Paraproteinemias: Clinical, Anatomopathological and Pathophysiological Study — MGRS-CAPS

Monoclonal Gammopathy of Renal Significance Clinical Trial

Official title:
Diagnosis of Monoclonal Gammopathy of Renal Significance in Patients With Paraproteinemias

Status Recruiting

Clinical Trial Summary

This is the first prospective study which evaluate patients with small B-cell clones to diagnose monoclonal gammopathy of renal significance (MGRS) and characterize it clinically, anatomopathologically and pathophysiologically taking int account a geriatric approach.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Monoclonal Gammopathy of Renal Significance
Monoclonal Gammopathy of Undetermined Significance
Paraproteinemias

Clinical Trial Details

NCT number	NCT03629561
Study type	Observational [Patient Registry]
Source	Academia Nacional de Medicina
Contact	Mariana Ciocchini, Nephrologist
Phone	+54 9 11 6172 2738
Email	marianaciocchini@pm.me
Status	Recruiting
Phase
Start date	February 23, 2019
Completion date	February 2021

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06083922` - A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)	Phase 2
Recruiting	`NCT06418477` - Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone Therapy for Patients With MIDD	Phase 2
Completed	`NCT05119309` - MGRS: Clinical-histological Features of a Multicenter Case Series